Bristol-Myers Squibb Company (BMY)

NYSE · Princeton, New Jersey, USA · Founded 1887 · CEO Christopher Boerner

Valuation summary

$101.92 fair value versus $58.34 in the market, a difference of +74.7%. Rated Strong Buy.

Fair value per share$101.92
Current share price$58.34
Upside / downside+74.7%
Bear case$69.53
Bull case$146.05
Discount rate (WACC)9.4%
Terminal growth2.00%
Market capitalisation$119B
EV / Sales3.0x

About Bristol-Myers Squibb Company

Traces to Bristol-Myers, founded 1887, merged with Squibb in 1989. Christopher Boerner became CEO in late 2023. Bristol Myers Squibb sells Eliquis, the leading blood thinner, and Opdivo, a foundational cancer immunotherapy. Both face loss of exclusivity within a few years, and the company has made a series of large acquisitions — Karuna, RayzeBio, Mirati — to rebuild the pipeline. Cobenfy, a novel schizophrenia treatment from Karuna, is the most important new launch.

Investment case

  • Cobenfy is the first genuinely new mechanism in schizophrenia in decades and addresses a large underserved population.
  • Trades at one of the lowest multiples in large-cap pharma with a substantial dividend.
  • Strong current cash generation funds both the dividend and continued business development.

Key risks

  • Eliquis and Opdivo together represent a very large share of revenue and both face exclusivity loss.
  • Recent acquisitions have been expensive and have not yet demonstrated returns.
  • US drug pricing reform disproportionately affects the highest-revenue products.

Recent developments

Revenue by segment

Oncology40%
Cardiovascular27%
Immunology20%
Neuroscience & Other13%

Five-year forecast

RevenueFree cash flow
Year 1$51.9B$17.7B
Year 2$54.1B$17.8B
Year 3$56.3B$17.8B
Year 4$58.6B$17.8B
Year 5$61.1B$17.8B

What the street says

A classic value-versus-patent-cliff debate, now focused on a cluster of pipeline readouts. In October 2026 Leerink downgraded to Market Perform with a $59 target, doubting milvexian against Eliquis, admilparant and Cobenfy in Alzheimer's disease psychosis, while Piper Sandler had raised its target to $82 in September on the same milestones.

Comparable companies: DHR · GSK · PFE · AMGN · NVO · GILD · ZTS · TAK

Open the interactive model, price chart and sensitivity grid →